Search results for Citius Pharmaceuticals

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain condition...

Citius Oncology sees first international shipment of LYMPHIR to Europe

Cranford-based Citius Oncology, Inc., an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc., announced the first shipment of L...

<![CDATA[Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst Pharmaceuticals ]]>

<![CDATA[Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement]]>

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

AQUESTIVE (AQST)

AQUESTIVE (AQST) Anonymous (not verified) Sun, 04/12/2026 - 05:04 field_thread_url https://cafepharma.com/boards/threads/aquestive-aqst.646620/...

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.

Revolution Medicines

Revolution Medicines Anonymous (not verified) Tue, 05/05/2026 - 02:20 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs

<![CDATA[Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics]]>

<![CDATA[FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection ]]>

Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics

Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-...

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

<![CDATA[Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement]...

Mirum Pharmaceuticals prices $600M senior notes

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

<![CDATA[Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher ]]>

Ensysce Biosciences Reports First Quarter 2026 Financial Results

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~~ Company Launche...

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.

Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential

Calliditas?

Calliditas? Anonymous (not verified) Fri, 04/24/2026 - 11:14 field_thread_url https://cafepharma.com/boards/threads/calliditas.661472/ b...

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

- Continued Advancement of CALMA Phase 2 Trial -

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>